Provided by Tiger Trade Technology Pte. Ltd.

SITE Centers Corp.

5.53
+0.11002.03%
Volume:1.26M
Turnover:6.95M
Market Cap:290.12M
PE:1.65
High:5.60
Open:5.53
Low:5.44
Close:5.42
52wk High:13.15
52wk Low:5.35
Shares:52.46M
Float Shares:52.25M
Volume Ratio:0.84
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.36
EPS(LYR):3.36
ROE:41.78%
ROA:-0.21%
PB:0.87
PE(LYR):1.65

Loading ...

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Nov 05, 2025

Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

GlobeNewswire
·
Nov 04, 2025

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

GlobeNewswire
·
Nov 04, 2025

Press Release: Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Dow Jones
·
Nov 04, 2025

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

GlobeNewswire
·
Nov 04, 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

GlobeNewswire
·
Nov 04, 2025

BRIEF-Site Centers Announces Sale Of Parker Pavilions

Reuters
·
Nov 04, 2025

Site Centers Corp expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

Site Centers Sells Parker Pavilions for $8.4 Million

Reuters
·
Nov 04, 2025

Site Centers Announces Sale of Parker Pavilions

THOMSON REUTERS
·
Nov 04, 2025

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

GlobeNewswire
·
Nov 03, 2025

Press Release: Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

Dow Jones
·
Oct 31, 2025

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

GlobeNewswire
·
Oct 30, 2025

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

GlobeNewswire
·
Oct 30, 2025

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

GlobeNewswire
·
Oct 30, 2025

New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire
·
Oct 30, 2025

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

GlobeNewswire
·
Oct 30, 2025

Site Centers Corp. to Release Third Quarter 2025 Results

Reuters
·
Oct 28, 2025

Site Centers Corp expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
Oct 24, 2025

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

GlobeNewswire
·
Oct 23, 2025